Replimune Group, Inc. (REPL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US76029N1063
Replimune Group, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Operating income | -261.63 m USD | -319.92 m USD |
| EBIT | -262.17 m USD | -321.32 m USD |
| Net income | -247.30 m USD | -313.94 m USD |
| Diluted EPS – continuing operations | -3.07 USD | -3.38 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
More stocks
- Distribution Solutions Group, Inc. (DSGR)
- Semitronix Corp. A (301095.SZ)
- Gas Malaysia Bhd (5209.KL)
- Vesuvius plc (VSVS.L)
- Liberty Latin America Ltd. (LILAK)
- WEALTHFRONT CORP (WLTH)
- Suzhou Hengmingda Electronic Technology Co Ltd (002947.SZ)
- Nyfosa AB (NYF.ST)
- LegoChem Biosciences Inc (141080.KQ)
- Lotte Energy Materials Corporation (020150.KS)
- Genius Sports Ltd (GENI)
- SONIDA SENIOR LIVING, INC. (SNDA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.